Digital Health & AI

A complete guide to Health Canada's pre-market guidance for machine learning-enabled medical devices (MLMD), published April 2026, covering predetermined change control plans (PCCP), data quality requirements, bias mitigation, lifecycle risk management, mandatory digital submissions, terms and conditions enforcement, and how Canada's approach compares to FDA and EU AI Act requirements.

How to test AI-enabled medical devices for algorithmic bias across demographic subgroups, validate fairness using statistical methods, document bias analysis for FDA 510(k) and EU MDR submissions, and implement ongoing post-market monitoring — based on FDA AI-enabled device TPLC draft guidance, EU AI Act high-risk requirements, and 2026 regulatory expectations.

How to conduct clinical evaluation for Software as a Medical Device (SaMD) — valid clinical association, analytical validation, and clinical performance under IMDRF N41, FDA requirements, and EU MDR Article 61, including generating clinical evidence without traditional clinical trials, real-world data strategies, and navigating the January 2026 FDA withdrawal of the SaMD clinical evaluation guidance.

Medtronic completed its acquisition of CathWorks for $585M in April 2026, adding the AI-powered FFRangio system for non-invasive coronary physiology assessment, and signed a definitive agreement to acquire Scientia Vascular for $550M in March 2026 for its microfabricated neurovascular guidewires and catheters. Covers how the AI-driven FFRangio system derives fractional flow reserve from routine angiograms, Scientia's nitinol microfabrication technology for stroke intervention, and Medtronic's post-MiniMed acquisition strategy focused on high-growth cardiovascular and neuroscience tuck-in deals.

Roche entered a definitive agreement to acquire PathAI on May 7, 2026, for $750M upfront plus up to $300M in milestone payments, adding the AISight digital pathology platform and AI-based biomarker algorithms to its diagnostics division. Covers PathAI's technology for cancer screening and companion diagnostic development, the $1.1B+ AI pathology market, regulatory considerations for AI/ML-based SaMD, and implications for precision oncology and IVD regulatory strategy.

GE HealthCare announced a sweeping restructuring of its business segments and executive leadership team alongside Q1 2026 earnings that missed expectations. Facing $250M in inflationary cost increases driven by memory chips, oil, and freight, the company is raising prices and cutting its profit outlook. Covers the new Advanced Imaging Solutions segment, leadership changes, the inflation impact on medtech supply chains, and what device manufacturers should expect.

In-depth analysis of Danaher's $9.9 billion acquisition of Masimo, the largest medtech deal of 2026. Covers deal structure, strategic rationale, regulatory and antitrust considerations, competitive landscape impact on patient monitoring, and what it means for device manufacturers, hospitals, and investors.

Comprehensive guide to the EU's new Breakthrough Device (BtX) framework under MDCG 2025-9 and the EMA pilot program launching Q2 2026. Covers eligibility criteria, application process, benefits for manufacturers, comparison with the FDA Breakthrough Device Program, and what this means for IVD companies.

Detailed analysis of MedTech Europe's May 2026 position paper on the proposed MDR/IVDR revision. Covers breakthrough/orphan pathways, cybersecurity, AI integration, IVDR-specific concerns, and what manufacturers need to know about the coming legislative process.

On May 7, 2026, the EU Council and Parliament reached a provisional deal to simplify AI Act rules. This guide breaks down what changed, what the product safety exemption means for medical devices, the new compliance timelines for AI-enabled SaMD and IVDs, and what manufacturers must do now.

Breaking down the FDA's May 2026 one-day inspection pilot that uses AI (Elsa) to target low-risk facilities. Covers how facilities are selected, what to expect during a screening inspection, how it differs from standard inspections, and what medical device manufacturers must do to stay ready.

The FDA's April 2026 real-time clinical trials initiative uses AI and cloud computing to monitor trial data as it is generated. This guide explains how the program works, the Paradigm Health platform, implications for medical device clinical investigations, and what sponsors must prepare to participate.

A field-by-field evidence matrix mapping MDR Annex II/III technical documentation, ISO 14971 risk management, PMS/PMCF, cybersecurity, data governance, human oversight, and QMS records to EU AI Act high-risk obligations — for manufacturers who must comply with both frameworks simultaneously.

A methodical approach to mining FDA's AI-enabled device list and 510(k) database for predicate devices — covering technological characteristic extraction, public summary limitations, weak predicate argument avoidance, and a complete predicate evaluation matrix.

How to build the Unresolved Software Anomalies table for FDA premarket cybersecurity submissions — CVSS scoring, exploitability assessment, clinical impact analysis, compensating controls, SBOM linkage, VEX status, labeling language, release criteria, and common reviewer objections.

A comprehensive guide to IEC 62304 Edition 2 — the 2026 update replacing safety classes A/B/C with rigor levels, expanding scope to all health software, adding AI/ML lifecycle requirements, integrating cybersecurity, and practical compliance timelines for medical device manufacturers.

Practical guide to change control for NGS bioinformatics pipelines in IVD devices — covering variant caller updates, reference database changes, threshold modifications, wet-lab/software interface validation, IEC 62304 documentation, revalidation triggers, and postmarket records.

How to design and implement a drift monitoring protocol for AI-enabled imaging devices under FDA PCCP — dataset shift, scanner drift, demographic drift, performance thresholds, monitoring cadence, retraining triggers, labeling changes, and when FDA submission is still required.

Operational playbook for medical device PSIRT teams — SBOM component matching, exploitability analysis, VEX justification authoring, PSIRT severity scoring, CAPA trigger thresholds, field safety corrective action decisions, and customer communication timing.

Decision tree for when a software or cybersecurity update can use Special 510(k) vs Traditional 510(k) — risk analysis, V&V summary, FDA guidance, and evidence package requirements.